These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
275 related articles for article (PubMed ID: 30223887)
21. Medullary thyroid carcinoma with double negative calcitonin and CEA: a case report and update of literature review. Gambardella C; Offi C; Clarizia G; Romano RM; Cozzolino I; Montella M; Di Crescenzo RM; Mascolo M; Cangiano A; Di Martino S; Candela G; Docimo G BMC Endocr Disord; 2019 Oct; 19(1):103. PubMed ID: 31619220 [TBL] [Abstract][Full Text] [Related]
22. Management of thyroid cancer: United Kingdom National Multidisciplinary Guidelines. Mitchell AL; Gandhi A; Scott-Coombes D; Perros P J Laryngol Otol; 2016 May; 130(S2):S150-S160. PubMed ID: 27841128 [TBL] [Abstract][Full Text] [Related]
24. Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times. Laure Giraudet A; Al Ghulzan A; Aupérin A; Leboulleux S; Chehboun A; Troalen F; Dromain C; Lumbroso J; Baudin E; Schlumberger M Eur J Endocrinol; 2008 Feb; 158(2):239-46. PubMed ID: 18230832 [TBL] [Abstract][Full Text] [Related]
25. Medullary thyroid cancer outcomes in patients with undetectable versus normalized postoperative calcitonin levels. Fanget F; Demarchi MS; Maillard L; Lintis A; Decaussin M; Lifante JC Br J Surg; 2021 Sep; 108(9):1064-1071. PubMed ID: 33899100 [TBL] [Abstract][Full Text] [Related]
26. Clinical and pathological analysis of 19 cases of medullary thyroid carcinoma without an increase in calcitonin. Zhou Q; Yue S; Cheng Y; Jin J; Xu H Exp Toxicol Pathol; 2017 Oct; 69(8):575-579. PubMed ID: 28552629 [TBL] [Abstract][Full Text] [Related]
27. Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma. Barbet J; Campion L; Kraeber-Bodéré F; Chatal JF; J Clin Endocrinol Metab; 2005 Nov; 90(11):6077-84. PubMed ID: 16091497 [TBL] [Abstract][Full Text] [Related]
28. Medullary thyroid carcinoma with nodular goiter carries an excellent prognosis. Xu L; Wang WB; Zhao YP; Zhang TP; Liao Q; Chen G; Zhou L; Shu H J Surg Oncol; 2012 Aug; 106(2):169-73. PubMed ID: 22354558 [TBL] [Abstract][Full Text] [Related]
29. Utility of serum procalcitonin for screening and risk stratification of medullary thyroid cancer. Machens A; Lorenz K; Dralle H J Clin Endocrinol Metab; 2014 Aug; 99(8):2986-94. PubMed ID: 24840813 [TBL] [Abstract][Full Text] [Related]
30. Early changes in carcinoembryonic antigen but not in calcitonin levels are correlated with the progression-free survival in medullary thyroid carcinoma patients treated with cytotoxic chemotherapy. Hajje G; Borget I; Leboulleux S; Chougnet C; Al Ghuzlan A; Mirghani H; Caramella C; Hartl D; Schlumberger M; Baudin E Eur J Endocrinol; 2013 Feb; 168(2):113-8. PubMed ID: 23093698 [TBL] [Abstract][Full Text] [Related]
31. Diagnostic utility of PET/CT with Romero-Lluch AR; Cuenca-Cuenca JI; Guerrero-Vázquez R; Martínez-Ortega AJ; Tirado-Hospital JL; Borrego-Dorado I; Navarro-González E Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):2004-2013. PubMed ID: 28646462 [TBL] [Abstract][Full Text] [Related]
33. [Usefulness of serum calcitonin, CEA and AFP assays in the early detection of medullary thyroid carcinoma relapse]. Łacka K; Michałek K; Majewski P Wiad Lek; 2002; 55(7-8):394-403. PubMed ID: 12428567 [TBL] [Abstract][Full Text] [Related]
34. Prognostic Value of Serum Tumor Markers in Medullary Thyroid Cancer Patients Undergoing Vandetanib Treatment. Werner RA; Schmid JS; Muegge DO; Lückerath K; Higuchi T; Hänscheid H; Grelle I; Reiners C; Herrmann K; Buck AK; Lapa C Medicine (Baltimore); 2015 Nov; 94(45):e2016. PubMed ID: 26559299 [TBL] [Abstract][Full Text] [Related]
35. High Ratio of Early Postoperative Calcitonin to Preoperative Calcitonin Could be a Novel Indicator of Poor Prognosis in Patients with Biochemical Incomplete Responses in Sporadic Medullary Thyroid Cancer. Chen L; Sun W; Qian K; Guo K; Sun T; Wu YI; Wang Z Endocr Pract; 2020 Jul; 26(7):738-747. PubMed ID: 33471642 [TBL] [Abstract][Full Text] [Related]
36. Disparity between tissue and serum calcitonin and carcinoembryonic antigen in a patient with medullary thyroid carcinoma. Alapat DV; Ain KB; Sloan DA; Monaghan KG; Karabakhtsian RG Endocrine; 2011 Apr; 39(2):148-52. PubMed ID: 21243446 [TBL] [Abstract][Full Text] [Related]
37. Static Prognostic Factors and Appropriate Surgical Designs for Patients with Medullary Thyroid Carcinoma: The Second Report from a Single-Institution Study in Japan. Ito Y; Miyauchi A; Kihara M; Higashiiyama T; Fukushima M; Miya A World J Surg; 2018 Dec; 42(12):3954-3966. PubMed ID: 30051240 [TBL] [Abstract][Full Text] [Related]
38. Medullary Thyroid Carcinoma: Prognostic Variables And Tumour Markers Affecting Survival. Hassan A; Siddique M; Riaz S; Khan AI; Nawaz MK; Bashir H J Ayub Med Coll Abbottabad; 2018; 30(Suppl 1)(4):S627-S632. PubMed ID: 30838820 [TBL] [Abstract][Full Text] [Related]
39. Serum calcitonin negative medullary thyroid carcinoma: a systematic review of the literature. Trimboli P; Giovanella L Clin Chem Lab Med; 2015 Sep; 53(10):1507-14. PubMed ID: 25781697 [TBL] [Abstract][Full Text] [Related]
40. Medullary thyroid carcinoma surgical cytoreduction induces an increase in serum calcitonin and carcinoembryonic antigen doubling times. Papapetrou PD; Polymeris A Exp Clin Endocrinol Diabetes; 2012 Mar; 120(3):164-8. PubMed ID: 22328112 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]